Compare AU
Compare IVV vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the S&P US 500 (IVV) and the BetaShares Global Healthcare ETF - Currency Hedged (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
IVV | DRUG | |
|---|---|---|
Popularity | High | Low |
Pearlers invested | 12,553 | 63 |
Median incremental investment | $1,000.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,048.96 | $1,875.72 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
IVV | DRUG | |
|---|---|---|
Strategy | iShares S&P 500 ETF (ASX: IVV) seeks to track the performance of the US S&P 500 index before account fees, expenses, and taxes. The index tracks the top 500 companies on the US stock market. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Microsoft Corporation (6.95 %) Apple, Inc. (5.75 %) NVIDIA Corporation (5.10 %) | CHF - SWISS FRANC (0 %) AUD - AUSTRALIA DOLLAR (0 %) DKK - DANISH KRONE (0 %) |
Top 3 industries | Other (99.97 %) Communication Services (0.00 %) | Other (75.53 %) Communication Services (33.53 %) Health Care (24.47 %) |
Top 3 countries | United States (99.92 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.04 % | 0.57 % |
Key Summary
IVV | DRUG | |
|---|---|---|
Issuer | iShares | BetaShares |
Tracking index | S&P 500 - AUD | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.04 % | 0.57 % |
Price | $63.52 | $8.12 |
Size | $10.979 billion | $191.120 million |
10Y return | 287.25 % | N/A |
Annual distribution yield (5Y) | 13.82 % | 1.90 % |
Market | ASX | ASX |
First listed date | 10/10/2007 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
IVV | DRUG | |
|---|---|---|
Popularity | High | Low |
Pearlers invested | 12,553 | 63 |
Median incremental investment | $1,000.00 | $967.00 |
Median investment frequency | Monthly | Monthly |
Median total investment | $3,048.96 | $1,875.72 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
IVV | DRUG | |
|---|---|---|
Pros |
| |
Cons |
|
IVV | DRUG |
|---|---|
Higher exposure to US market | Lower exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |